November 5, 2020 - XenoTherapeutics, a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs, has completed the first of two patient cohorts in the company’s Phase I clinical trial of Xeno-Skin®. As a result, the U.S. Food and Drug Administration (FDA) has agreed to permit accelerated patient enrollment; patients may now enroll in the trial’s second cohort simultaneously. No adverse events or safety issues have been observed or reported to date; in all patients, Xeno-Skin® and the human skin comparator were indistinguishable at the time of autografting. Learn More »

April 4, 2019 - XenoTherapeutics, Inc., a regenerative medicine company specializing in xenotransplantation, received the Burke/Yannas Award for Best Bioengineering Paper today at the 51st conference of the American Burn Association for its research of Xeno-Skin®. Co-founders Paul Holzer, CEO and Jon Adkins, COO, accepted the award on the company’s behalf. Learn More »

December 8, 2018 - XenoTherapeutics, a life science company whose mission is to solve the global shortage of organs and tissues for transplants, announced today that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application (IND #18194) allowing clinical studies of Xeno-Skin® to be initiated. Xeno-Skin is a first-of-its-kind xenotransplantation product, designed to provide a safe temporary coverage mechanism for patients with severe burn wounds. The company is inactive preparations to enroll patients for a first-in-human clinical study of Xeno-Skin® at Massachusetts General Hospital (MGH) by the end of 2018. Learn More »